In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Clinical research worldwide is rapidly transforming through new digital strategies—especially in the field of rare diseases. Recent months …
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Manufacturing breakthroughs are set to transform cell therapy production, paving the way for faster trials and wider patient …
Already a subscriber? Log in